Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 32Vincristine 22blinatumomab 20Methotrexate 20Specimen Handling 19Prednisone 19Cytarabine 17merphos 16prednylidene 15deltacortene 15Biopsy 15Mercaptopurine 14Doxorubicin 14Dexamethasone 14N,N-dicyclohexyl-isoborneol-10-sulfonamide 13pegaspargase 12azathiopurine 12Rituximab 12Etoposide 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11Spinal Puncture 11Calcium Dobesilate 11Asparaginase 11Leucovorin 10fludarabine 9Magnetic Resonance Spectroscopy 9Inotuzumab Ozogamicin 9Daunorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × nelarabine × 90 days × Clear all
NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
53 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡